Teva Pharmaceutical Industries Ltd
F:TEV
Teva Pharmaceutical Industries Ltd
F:TEV
Price:
24.6
EUR
-7.17%
Market Closed
Market Cap:
€27.9B
Relative Value
The Relative Value of one
TEV
stock under the Base Case scenario is
23.73
EUR.
Compared to the current market price of 24.6 EUR,
Teva Pharmaceutical Industries Ltd
is
Overvalued by 4%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TEV
Relative Value
Base Case
23.73
EUR
Overvaluation 4%
Multiples Across Competitors
TEV Competitors Multiples
Teva Pharmaceutical Industries Ltd Competitors
Teva Pharmaceutical Industries Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
|
Teva Pharmaceutical Industries Ltd
F:TEV
|
104.6B EUR | 2 | 23.9 | 8.8 | 10.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
939.9B USD | 14.4 | 45.3 | 30.6 | 32.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
587.8B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
256.9B CHF | 4.2 | 19.8 | 11.7 | 13.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.3B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
234.4B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
288.2B USD | 4.4 | 15.8 | 9.8 | 12 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.5B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
